Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $136

Benzinga Newsdesk www.benzinga.com Positive 86.1%

Neg 0% Neu 0% Pos 86.1%

Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $116 to $136.